There is considerable discussion in the media (social and otherwise) about semaglutide (Wegovy), one of a class of drugs now approved for the treatment of obesity. Of further interest is the potential usefulness of these agents in a range of neurodegenerative disorders, including MS, Alzheimer’s disease and Parkinson disease. Read More
Latest News
Putting shared decision-making into practice
February 16, 2023Three elements
Decision aids
Use of patient-reported outcome measures (PROMs)
Switching therapy
SDM: strengths and limitations
The concept of shared decision-making (SDM) has gained momentum in recent years as the preferred approach to MS care. The emergence of SDM two decades ago can be traced back to an acknowledgement of the greater role patients wanted to play in their care decisions, in part due to the recognition that patients’ treatment goals may differ from those of the clinician (Kumar et al. Patient Prefer Adherence 2021;15:1515-1527); and a proliferation of treatments that were similar so that medication choices were preference-sensitive. The advent of social media provided a further spur to patients’ notions of empowerment and participatory medicine (Kantor et al. Neurol Ther 2018;7:37-49). Read More
CLINICAL CASES IN MS – AN OLDER PATIENT WITH STABLE DISEASE
February 9, 2023Click here to watch Dr. Courtney Casserly discuss the case and the responses to the survey.
Janet, 58, currently works full-time running an animal grooming business. She is married with two adult children. She was diagnosed in 1997 with RRMS after presenting with two mild relapses. MRI at that time revealed a low T2 burden of disease. She was initially hesitant about starting treatment. In 2003, she initiated therapy with interferon-beta-1b after experiencing a moderately-severe relapse with some residual disability. EDSS was 1.5. Read More
The end of MS phenotypes?
January 26, 2023The International Advisory Committee on Clinical Trials in Multiple Sclerosis is recommending that the clinical course descriptions of MS – relapsing-remitting (RRMS), secondary-progressive (SPMS) and primary-progressive (PPMS) – be discarded in favour of a more biology-based approach (Kuhlmann et al. Lancet Neurol 2022; epublished November 18, 2022). Read More